1. Home
  2. ASMB vs FDMT Comparison

ASMB vs FDMT Comparison

Compare ASMB & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$27.84

Market Cap

499.8M

Sector

Health Care

ML Signal

HOLD

Logo 4D Molecular Therapeutics Inc.

FDMT

4D Molecular Therapeutics Inc.

HOLD

Current Price

$8.04

Market Cap

431.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASMB
FDMT
Founded
2005
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
499.8M
431.4M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
ASMB
FDMT
Price
$27.84
$8.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
7
Target Price
$43.40
$34.29
AVG Volume (30 Days)
109.9K
747.3K
Earning Date
11-10-2025
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$37,191,000.00
$120,000.00
Revenue This Year
$33.33
$21,227.03
Revenue Next Year
N/A
$161.87
P/E Ratio
N/A
N/A
Revenue Growth
31.30
605.88
52 Week Low
$7.75
$2.24
52 Week High
$39.71
$12.34

Technical Indicators

Market Signals
Indicator
ASMB
FDMT
Relative Strength Index (RSI) 37.34 46.64
Support Level $25.93 $7.30
Resistance Level $32.31 $7.80
Average True Range (ATR) 1.74 0.53
MACD -0.43 0.14
Stochastic Oscillator 25.06 55.27

Price Performance

Historical Comparison
ASMB
FDMT

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About FDMT 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Share on Social Networks: